Cytek Biosciences Inc. (CTKB)
4.30
-0.19 (-4.23%)
At close: Mar 03, 2025, 3:59 PM
4.30
-0.12%
After-hours: Mar 03, 2025, 04:00 PM EST
Cytek Biosciences Inc. Revenue Breakdown
Quarter | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product Revenue | 39.54M | 34.12M | 46.65M | 38.44M | 40.45M | 31.17M | 43.64M | 36.39M | 37.09M | 31.48M | 35.95M | 32.19M | 28.92M |
Product Revenue Growth | +15.89% | -26.86% | +21.36% | -4.97% | +29.77% | -28.57% | +19.92% | -1.90% | +17.83% | -12.44% | +11.68% | +11.30% | n/a |
Service Revenue | 39M | 36.87M | 0 | 37M | 9.24M | 5.92M | 4.7M | 4.09M | 3.07M | 3.58M | 2.94M | 2.19M | 12.47M |
Service Revenue Growth | +5.78% | n/a | -100.00% | +300.38% | +56.20% | +25.90% | +14.95% | +33.33% | -14.43% | +21.79% | +34.65% | -82.48% | n/a |
Revenue by Geography
Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
---|---|---|---|
Asia Pacific Revenue | 31.6M | 22.52M | 16.08M |
Asia Pacific Revenue Growth | +40.29% | +40.09% | n/a |
Emea Revenue | 53.18M | 43.96M | 36.97M |
Emea Revenue Growth | +20.97% | +18.91% | n/a |
Other Revenue | 6.15M | 2.96M | 2.18M |
Other Revenue Growth | +107.69% | +35.86% | n/a |
United States Revenue | 102.08M | 94.59M | 72.72M |
United States Revenue Growth | +7.92% | +30.07% | n/a |
Operating Expense Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 23.37M | 23.96M | 23.95M | 22.32M | 22.43M | 25.15M | 23.23M | 19.54M | 16.85M | 17.02M | 14.51M | 15.23M | 12.24M | 9.74M | 8.26M | 7.19M | 5.53M | 5.57M | 6.07M |
Selling, General, and Administrative Revenue Growth | -2.47% | +0.05% | +7.33% | -0.49% | -10.84% | +8.30% | +18.85% | +15.97% | -0.96% | +17.28% | -4.75% | +24.49% | +25.63% | +17.92% | +14.91% | +30.01% | -0.77% | -8.19% | n/a |
Research and Development Revenue | 9.88M | 10M | 9.8M | 10.87M | 11.17M | 12.14M | 9.97M | 9.75M | 8.65M | 8.44M | 8.03M | 7.08M | 6.08M | 6.19M | 5.09M | 4.38M | 3.38M | 2.92M | 3.02M |
Research and Development Revenue Growth | -1.19% | +2.09% | -9.87% | -2.70% | -7.95% | +21.68% | +2.33% | +12.68% | +2.54% | +5.12% | +13.41% | +16.42% | -1.87% | +21.59% | +16.17% | +29.89% | +15.78% | -3.32% | n/a |
Sales and Marketing Revenue | 12.43M | 12.27M | 12.54M | 11.56M | 12.08M | 14.37M | 11.14M | 9.03M | 8.81M | 8.43M | 6.96M | 8.3M | 6.33M | 5.58M | 4.28M | 4.56M | 3.84M | 3.06M | 3.53M |
Sales and Marketing Revenue Growth | +1.31% | -2.19% | +8.49% | -4.26% | -15.95% | +28.91% | +23.44% | +2.49% | +4.50% | +21.14% | -16.18% | +31.16% | +13.54% | +30.37% | -6.21% | +18.81% | +25.47% | -13.37% | n/a |